# Centre for Commercialization of Cancer Immunotherapy

> Centre for Commercialization of Cancer Immunotherapy is a VC fund backing Biotechnology. See 2 investments, check sizes, portfolio and contact details…

- Type: VC Fund
- Location: Montréal, Canada
- Total investments: 2
- Last investment: Mar 2023
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/c3i-centre-for-commercialization-of-cancer-immunotherapy/about/
- Website: https://centrec3i.com/

Centre for Commercialization of Cancer Immunotherapy is a VC fund in Montréal focused on Biotechnology and Health Care. Centre for Commercialization of Cancer Immunotherapy is to Accelerate the discovery, commercialization, and access to Cancer Immunotherapy.

## Contacts

5 contacts available for Centre for Commercialization of Cancer Immunotherapy. Shizune tracks 2 team members at Centre for Commercialization of Cancer Immunotherapy. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/centre-for-commercialization-of-cancer-immunotherapy?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Health Care | 1 | 50% |
| Life Science | 1 | 50% |
| Clinical Trials | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Pre-Seed | 1 | 50% |
| Series A | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Canada | 1 | 50% |
| United States | 1 | 50% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Bobby Boursiquot | Vice President of Commercialization | 0 | https://shizune.co/investors/profile/bobby-boursiquot-f93f |
| Yvan Côté | President and CEO | 0 | https://shizune.co/investors/profile/yvan-c%C3%B4t%C3%A9 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Inspire Biotherapeutics | Inspire Biotherapeutics' objective is to create curative gene therapies for those suffering from lung ailments. |  | Pre-Seed | Mar 15, 2023 |  |
| Triumvira Immunologics | Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cellreceptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer. | $55M | Series A | Aug 27, 2020 |  |

2 of 2 investments shown.

## Co-investors
- [Leaps by Bayer](https://shizune.co/investors/profile/leaps-by-bayer) — VC Fund, 2 deals together
- Bloom Burton & Co. — VC Fund, 1 deal together
- [Northpond Ventures](https://shizune.co/investors/profile/northpond-ventures) — VC Fund, 1 deal together
- [Oceanpine Capital](https://shizune.co/investors/profile/oceanpine-capital) — VC Fund, 1 deal together
- [Octane](https://shizune.co/investors/profile/octane-dafb) — VC Fund, 1 deal together
- [Ontario Institute For Regenerative Medicine](https://shizune.co/investors/profile/ontario-institute-for-regenerative-medicine) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund

### Similar country
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund
- [Real Ventures](https://shizune.co/investors/profile/real-ventures) — VC Fund
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund

## Featured in investor lists
- [Life Science Investors in Canada](https://shizune.co/investors/life-science-investors-canada)

## FAQ

### What does Centre for Commercialization of Cancer Immunotherapy invest in?

Centre for Commercialization of Cancer Immunotherapy invests primarily in Biotechnology, Health Care and Life Science startups, most often at Pre-Seed and Series A stage. Most of the 2 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Centre for Commercialization of Cancer Immunotherapy?

Public channels for Centre for Commercialization of Cancer Immunotherapy include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Centre for Commercialization of Cancer Immunotherapy?

The team at Centre for Commercialization of Cancer Immunotherapy includes Bobby Boursiquot (Vice President of Commercialization) and Yvan Côté (President and CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co